Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
| Autor: | Dana Gelbaum, Shuqian Liu, Daphne T. Adelman, William H. Ludlam, Asi Haviv, Jill Sisco, Susan D. Mathias, Lizheng Shi, Eliza B Geer |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Endocrinology Diabetes and Metabolism Concordance 030209 endocrinology & metabolism Medical provider Article Somatostatin receptor ligands Treatment satisfaction 03 medical and health sciences 0302 clinical medicine Endocrinology Surveys and Questionnaires Acromegaly Injection site medicine Humans In patient Receptors Somatostatin Patient reported outcomes Normal range 030203 arthritis & rheumatology Questionnaire business.industry Middle Aged medicine.disease Female General health Somatostatin business |
| Zdroj: | Pituitary |
| ISSN: | 1573-7403 1386-341X |
| Popis: | Background Acromegaly patients, even those with IGF-1 values within the normal range receiving somatostatin receptor ligands (SRLs), often suffer from significant symptoms. It is not known to what extent patients’ medical providers are aware of the frequency and severity of acromegaly symptoms or level of treatment satisfaction with SRLs. This study sought to examine the concordance between outcomes reported by acromegaly patients treated with long-acting SRLs and those perceived by their medical provider. Methods US acromegaly patients on a stable dose of SRL and seen by their medical provider in the past year completed an online survey which included the Acro-TSQ. Their medical providers were interviewed about the perception of their patient’s symptoms, level of control, and general health, and completed relevant portions of the Acro-TSQ. Concordance between patient and medical provider reported data was examined. Results Medical providers reported that their patients experienced acromegaly symptoms on a regular basis, however, there was poor agreement between patients and medical providers on the frequency, severity, and pattern of symptoms, as well as on the severity of injection site reactions and multiple domains of the Acro-TSQ, with patients generally reporting symptoms and injection site reactions more often and with higher severity than medical providers. Conclusions Medical providers were aware that their patients who were receiving a stable dose of SRL regularly experienced acromegaly symptoms. Addressing discordance in patient- and medical provider-reported frequency and severity of acromegaly symptoms and injection site reactions by facilitating better communication may improve care of acromegaly patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink